Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shot up 7.9% during mid-day trading on Tuesday . The stock traded as high as GBX 1.47 ($0.02) and last traded at GBX 1.47 ($0.02). 5,676,613 shares traded hands during trading, a decline of 39% from the average session volume of 9,259,996 shares. The stock had previously closed at GBX 1.36 ($0.02).
Hemogenyx Pharmaceuticals Trading Up 8.4 %
The stock’s fifty day moving average is GBX 1.38 and its 200 day moving average is GBX 1.37. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38. The stock has a market cap of £20.84 million, a P/E ratio of -143.50 and a beta of 3.14.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Featured Articles
- Five stocks we like better than Hemogenyx Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- 3 Warren Buffett Stocks to Buy Now
- Williams-Sonoma Stock: Buy It and Never Let It Go
- The Most Important Warren Buffett Stock for Investors: His Own
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
